Brazilian children from the Yanomami indigenous community will be the first in the world to get a single-dose paediatric treatment for relapsing malaria. The introduction of paediatric tafenoquine, developed by Medicines for Malaria Venture (MMV) and pharmaceutical  company GSK, marks a “major step” towards closing the treatment gap for children at risk of relapsing Plasmodium […] Continue reading ->
Scientists working on new malaria drugs now have access to an open-access artificial intelligence (AI)-powered platform  aimed at accelerating drug discovery, thanks to a partnership between  Medicines for Malaria Venture (MMV) and deepmirror. Drug Design for Global Health (dd4gh) uses “both predictive and generative AI to give researchers, especially those in the most resource-limited settings, […] Continue reading ->
Every $1 invested in the Medicines for Malaria Venture (MMV) between 2000 and 2023 yielded $13 in monetised health benefits, according to a study published in The Lancet Global Health this week. MMV is a not-for-profit product development partnership (PDP) that works with public and private sector partners to discover, develop and deliver accessible and […] Continue reading ->
The $9.4 billion package agreed to by the US Senate and House Appropriations Committees, is more than double the $3.7 billion requested by the Trump Administration, and signals bipartisan support for maintaining significant global health aid – although the package still must be approved by both Senate and House, and could also be vetoed by […] Continue reading ->
In Kenya, toxicologists and epidemiologists face a difficult choice: to pursue better-paid work to support their families, or volunteer as reviewers for vaccine clinical trials, often without the compensation needed to cover even their children’s school fees. Their dilemma underscores a broader challenge in Africa’s clinical research ecosystem. Slow, duplicative approval processes and limited regulatory […] Continue reading ->